Cargando…
Postinfectious Hemolytic Uremic Syndrome
Post-infectious hemolytic uremic syndrome (HUS) is caused by specific pathogens in patients with no identifiable HUS-associated genetic mutation or autoantibody. The majority of episodes is due to infections by Shiga toxin (Stx) producing Escherichia coli (STEC). This chapter reviews the epidemiolog...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121170/ http://dx.doi.org/10.1007/978-3-662-52972-0_26 |
_version_ | 1783515142600785920 |
---|---|
author | Bitzan, Martin Lapeyraque, Anne-Laure |
author_facet | Bitzan, Martin Lapeyraque, Anne-Laure |
author_sort | Bitzan, Martin |
collection | PubMed |
description | Post-infectious hemolytic uremic syndrome (HUS) is caused by specific pathogens in patients with no identifiable HUS-associated genetic mutation or autoantibody. The majority of episodes is due to infections by Shiga toxin (Stx) producing Escherichia coli (STEC). This chapter reviews the epidemiology and pathogenesis of STEC-HUS, including bacterial-derived factors and host responses. STEC disease is characterized by hematological (microangiopathic hemolytic anemia), renal (acute kidney injury) and extrarenal organ involvement. Clinicians should always strive for an etiological diagnosis through the microbiological or molecular identification of Stx-producing bacteria and Stx or, if negative, serological assays. Treatment of STEC-HUS is supportive; more investigations are needed to evaluate the efficacy of putative preventive and therapeutic measures, such as non-phage-inducing antibiotics, volume expansion and anti-complement agents. The outcome of STEC-HUS is generally favorable, but chronic kidney disease, permanent extrarenal, mainly cerebral complication and death (in less than 5 %) occur and long-term follow-up is recommended. The remainder of this chapter highlights rarer forms of (post-infectious) HUS due to S. dysenteriae, S. pneumoniae, influenza A and HIV and discusses potential interactions between these pathogens and the complement system. |
format | Online Article Text |
id | pubmed-7121170 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
record_format | MEDLINE/PubMed |
spelling | pubmed-71211702020-04-06 Postinfectious Hemolytic Uremic Syndrome Bitzan, Martin Lapeyraque, Anne-Laure Pediatric Kidney Disease Article Post-infectious hemolytic uremic syndrome (HUS) is caused by specific pathogens in patients with no identifiable HUS-associated genetic mutation or autoantibody. The majority of episodes is due to infections by Shiga toxin (Stx) producing Escherichia coli (STEC). This chapter reviews the epidemiology and pathogenesis of STEC-HUS, including bacterial-derived factors and host responses. STEC disease is characterized by hematological (microangiopathic hemolytic anemia), renal (acute kidney injury) and extrarenal organ involvement. Clinicians should always strive for an etiological diagnosis through the microbiological or molecular identification of Stx-producing bacteria and Stx or, if negative, serological assays. Treatment of STEC-HUS is supportive; more investigations are needed to evaluate the efficacy of putative preventive and therapeutic measures, such as non-phage-inducing antibiotics, volume expansion and anti-complement agents. The outcome of STEC-HUS is generally favorable, but chronic kidney disease, permanent extrarenal, mainly cerebral complication and death (in less than 5 %) occur and long-term follow-up is recommended. The remainder of this chapter highlights rarer forms of (post-infectious) HUS due to S. dysenteriae, S. pneumoniae, influenza A and HIV and discusses potential interactions between these pathogens and the complement system. 2016-06-17 /pmc/articles/PMC7121170/ http://dx.doi.org/10.1007/978-3-662-52972-0_26 Text en © Springer-Verlag Berlin Heidelberg 2016 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Bitzan, Martin Lapeyraque, Anne-Laure Postinfectious Hemolytic Uremic Syndrome |
title | Postinfectious Hemolytic Uremic Syndrome |
title_full | Postinfectious Hemolytic Uremic Syndrome |
title_fullStr | Postinfectious Hemolytic Uremic Syndrome |
title_full_unstemmed | Postinfectious Hemolytic Uremic Syndrome |
title_short | Postinfectious Hemolytic Uremic Syndrome |
title_sort | postinfectious hemolytic uremic syndrome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121170/ http://dx.doi.org/10.1007/978-3-662-52972-0_26 |
work_keys_str_mv | AT bitzanmartin postinfectioushemolyticuremicsyndrome AT lapeyraqueannelaure postinfectioushemolyticuremicsyndrome |